Paediatrics
Paediatrics

Global, regional, and national burden of congenital musculoskeletal and limb anomalies, 1990-2021: a systematic analysis of the global burden of disease in 2021

Trop Med Health. 2025 May 12;53(1):68. doi: 10.1186/s41182-025-00750-4. ABSTRACT BACKGROUND: Congenital musculoskeletal and limb (CML) anomalies are uncommon, multifactorial conditions whose global incidence trends remain …

Explainable predictive models of short stature and exploration of related environmental growth factors: a case-control study

BMC Endocr Disord. 2025 May 12;25(1):129. doi: 10.1186/s12902-025-01936-x. ABSTRACT BACKGROUND: Short stature is a prevalent pediatric endocrine disorder for which early detection and prediction are …

Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies

Atherosclerosis. 2025 May 7;405:119219. doi: 10.1016/j.atherosclerosis.2025.119219. Online ahead of print. ABSTRACT BACKGROUND: Patients with cancer treated with immune checkpoint inhibitors are at increased risk of …

Connectivity-map unveils Gemcitabine’s efficacy in overcoming nelarabine resistance in T-cell acute lymphoblastic leukemia

Biochem Biophys Res Commun. 2025 May 8;769:151971. doi: 10.1016/j.bbrc.2025.151971. Online ahead of print. ABSTRACT Resistance to Nelarabine, the primary FDA-approved therapy for relapsed/refractory T-cell acute …

Enhancing Access to Neuraxial Ultrasound Phantoms for Medical Education of Pediatric Anesthesia Trainees: Tutorial

JMIR Med Educ. 2025 May 12;11:e63682. doi: 10.2196/63682. ABSTRACT Opportunities to learn ultrasound-guided/assisted (USGA) neuraxial techniques for pediatric patients are limited, given the inherent high …

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia

J Clin Oncol. 2025 May 12:JCO2301965. doi: 10.1200/JCO.23.01965. Online ahead of print. ABSTRACT PURPOSE: This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557) compared efficacy of gemcitabine/nab-paclitaxel …